Angion’s HGF Mimetic Fails Second Phase II Study, But Not Shuttered Yet
Executive Summary
Although ANG-3777, partnered with Vifor, missed its primary endpoint in cardiovascular surgery patients at risk for acute kidney injury, the companies will consider a path forward based on a renal events measure.
You may also be interested in...
Vifor Builds Its Kidney Disease Focus With $80m Angion Deal
Deal helps Vifor pursue goal of becoming a leader in kidney disease therapies.
Vertex Adds To Myotonic Dystrophy Effort With Entrada Collaboration
Entrada gets $250m cash and equity up front under four-year deal, which extends its runway and will enable it to focus on Duchenne muscular dystrophy. Vertex further diversifies its pipeline with a novel drug class.
TherapeuticsMD Finds New Exit With Mayne Pharma Licensing Pact
After failure to close of a potential $177m buyout by EW Pharma, TherapeuticsMD will resolve its debt by selling its three-product women’s health portfolio to Mayne.